Dr Lal PathLabs Q3 FY26: revenue 6598 M, PAT 914 M, 3rd interim dividend 3.5/share
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Smallcap 250 and 0.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lal PathLabs posted Q3 FY26 consolidated revenue from operations of 6,598 M (up 10.6% YoY) and PAT of 914 M (down 6.8% YoY). For 9M FY26, revenue was 20,602 M (up 10.8%) and PAT was 3,776 M (up 12.1%). Board declared 3rd interim dividend of 3.5 per share with record date Feb 5, 2026. Results carry a 301 M exceptional charge for Labour Codes impact on gratuity and leave liabilities. Bonus shares 1:1 were allotted on December 22, 2025, and EPS for prior periods is restated accordingly.
Q3 PAT dipped YoY due to the one-time Labour Codes charge; underlying revenue and 9M PAT growth remain healthy; third interim dividend rewards shareholders.